안과용 점탄성 물질 시장 : 제품 유형, 조성, 포장 형태, 용도, 최종사용자, 유통 채널별 - 세계 예측(2026-2032년)

The Ophthalmic Viscosurgical Devices Market is projected to grow by USD 4.18 billion at a CAGR of 6.68% by 2032.

Ophthalmic viscosurgical devices (OVDs) are essential sterile viscoelastic products used to maintain intraocular space, protect the corneal endothelium, stabilize ocular tissues, and support lens implantation during cataract and other anterior segment surgeries. Commonly formulated with sodium hyaluronate, chondroitin sulfate, or hydroxypropyl methylcellulose, OVDs are selected according to viscosity, cohesion, dispersion, retention, and removability.

Demand for ophthalmic viscosurgical devices is closely tied to cataract surgery volumes, aging demographics, broader access to ophthalmic care, and the continued shift toward day-care and ambulatory surgical settings. Verified public health sources, including the World Health Organization and the United Nations, consistently identify cataract-related vision impairment and population aging as major structural drivers for ophthalmic procedure demand, reinforcing the clinical importance of safe, high-performance OVDs in modern cataract surgery.

Transformative Shifts in the OVD Landscape

The OVD landscape is shifting from basic surgical adjuncts toward procedure-specific, performance-differentiated products. Cohesive, dispersive, and viscoadaptive OVDs are increasingly selected based on surgical complexity, endothelial protection needs, ease of removal, anterior chamber stability, and compatibility with intraocular lenses and phacoemulsification systems.

Regulatory expectations, hospital procurement controls, sterile packaging quality, and single-use safety standards are also reshaping competition. Manufacturers are prioritizing reliable syringe delivery, validated biocompatibility, surgeon training, and supply continuity as ophthalmology providers seek predictable outcomes, efficient operating room workflows, and lower complication risk across routine and complex cataract procedures.

Cumulative Impact of Artificial Intelligence on OVDs

Artificial intelligence is influencing the ophthalmic viscosurgical devices market indirectly but materially. AI-enabled diagnostics, cataract grading, surgical planning, IOL power calculation support, operating room scheduling, and post-operative outcome analytics are improving cataract surgery workflows, which in turn affects product utilization, case planning, procurement timing, and inventory management.

For manufacturers and distributors, AI supports demand sensing, complaint trend analysis, quality management, clinical education, and real-world evidence generation. While AI does not replace OVDs, it strengthens data-driven decision-making across product development, surgeon engagement, procurement planning, and patient pathway optimization, particularly in high-volume cataract surgery settings.

Key Regional Insights for OVD Growth

Asia-Pacific is a high-priority region for ophthalmic viscosurgical devices because of its large aging population, expanding cataract surgery capacity, and increasing public and private investment in eye care. China, India, Japan, South Korea, Australia, and ASEAN countries are strengthening surgical infrastructure, widening access to cataract services, and creating demand for affordable, high-quality OVD options that can support both high-volume outreach programs and premium ophthalmic procedures.

North America remains a mature region with advanced cataract surgery adoption, strong ambulatory surgery center networks, rigorous product quality expectations, and established reimbursement pathways. Europe is shaped by clinical quality standards, procurement discipline, and EU Medical Device Regulation requirements, while Latin America is advancing through private ophthalmology centers, urban specialty clinics, and growing access to cataract surgery despite persistent affordability and geographic disparities. The Middle East is investing in specialty eye hospitals, advanced surgical platforms, and medical tourism, whereas Africa presents long-term opportunity as cataract surgical access, ophthalmic workforce training, donor-supported eye health initiatives, and affordability improve.

Key Group Insights Across Strategic Markets

ASEAN markets benefit from rising healthcare access, growing ophthalmology capacity, and regional medical tourism, particularly where private eye-care networks are expanding and governments are prioritizing avoidable blindness reduction. The GCC is supported by specialty care investment, high per-capita healthcare spending in key countries, and demand for advanced cataract and refractive procedures that require consistent OVD performance and dependable sterile supply.

The European Union is a quality-driven market where MDR compliance, traceability, clinical evidence, and post-market surveillance influence product selection and procurement decisions. BRICS countries represent volume-led opportunity due to large populations, expanding surgical capacity, and significant cataract burden, while G7 markets remain innovation-focused, reimbursement-sensitive, and clinically demanding. NATO member countries increasingly emphasize medical supply resilience, regulatory alignment, continuity planning, and dependable access to critical healthcare products, including single-use ophthalmic surgical consumables.

Key Country Insights for OVD Demand

The United States leads through high cataract procedure volumes, ambulatory surgery centers, premium IOL adoption, and strong use of advanced surgical technologies, while Canada emphasizes publicly funded access, quality-based procurement, and standardized clinical pathways. Mexico and Brazil show growth from private ophthalmology networks, urban specialty clinics, and demand for cost-effective ophthalmic viscosurgical devices that maintain safety and usability across diverse care settings.

The United Kingdom, Germany, France, Italy, and Spain remain important European countries where aging populations, cataract backlogs, hospital quality standards, and procurement scrutiny support sustained OVD demand. Russia continues to rely on domestic capacity and selective imports, with procurement influenced by localization policies and healthcare system priorities. China and India offer large-scale opportunities tied to cataract burden, population aging, surgical access expansion, and public eye health programs, while Japan, Australia, and South Korea favor high-quality devices, surgeon preference, advanced clinical protocols, and strong emphasis on patient safety and procedural precision.

Actionable Recommendations for Industry Leaders

Industry leaders should align OVD portfolios with surgeon-specific use cases, including endothelial protection, chamber maintenance, complex cataract cases, small-pupil management, premium IOL implantation, and efficient removal after phacoemulsification. Differentiated product education and evidence-based positioning are critical as hospitals, ophthalmology clinics, and ambulatory surgical centers evaluate value, safety, consistency, and workflow efficiency.

Manufacturers should strengthen regulatory documentation, sterile supply reliability, localized distribution, traceability, and post-market surveillance. Commercial teams should prioritize high-volume cataract markets, build partnerships with ophthalmic training institutions, improve surgeon familiarity with cohesive, dispersive, and viscoadaptive OVDs, and use AI-supported forecasting to reduce stockouts, enhance tender readiness, and improve procurement planning.

Research Methodology

This executive summary is based on a structured secondary research approach using public health, regulatory, demographic, and healthcare infrastructure indicators from recognized sources such as the World Health Organization, United Nations population datasets, national health agencies, peer-reviewed ophthalmology literature, and medical device regulatory frameworks.

Market interpretation integrates cataract procedure drivers, OVD product segmentation, clinical use cases, regional healthcare access, reimbursement dynamics, supply-chain considerations, regulatory requirements, and technology adoption patterns. Insights are validated through cross-comparison of clinical practice trends, ophthalmology service expansion, avoidable blindness priorities, and medical device commercialization factors, while avoiding market sizing, market share, and forecasting claims.

Conclusion

The ophthalmic viscosurgical devices market is positioned for steady expansion as cataract surgery demand rises, surgical techniques evolve, and healthcare systems prioritize vision restoration. OVDs remain indispensable to anterior segment surgery because they directly support safety, visualization, tissue protection, chamber stability, and procedural control.

Future competitiveness will depend on product reliability, regulatory readiness, clinical evidence, surgeon education, sterile manufacturing quality, and regional access strategies. Organizations that combine device quality with data-enabled commercialization, resilient distribution, and strong clinical support will be best positioned in this essential ophthalmic surgical category.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Ophthalmic Viscosurgical Devices Market, by Product Type

• 7.1. Cohesive
• 7.2. Combined
• 7.3. Dispersive
• 7.4. Viscoadaptive

8. Ophthalmic Viscosurgical Devices Market, by Composition

• 8.1. Combination
• 8.2. Hydroxypropyl Methylcellulose
• 8.3. Sodium Hyaluronate

9. Ophthalmic Viscosurgical Devices Market, by Packaging Format

• 9.1. Pre-Filled Syringes
  • 9.1.1. Single-use syringes
  • 9.1.2. Dual-chamber syringes
• 9.2. Vials
• 9.3. Procedure Kits

10. Ophthalmic Viscosurgical Devices Market, by Application

• 10.1. Cataract Surgery
• 10.2. Corneal Surgery
  • 10.2.1. Keratoplasty
  • 10.2.2. Keratoplasty
• 10.3. Glaucoma Surgery
• 10.4. Vitreoretinal Surgery

11. Ophthalmic Viscosurgical Devices Market, by End User

• 11.1. Ambulatory Surgery Centers
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Ophthalmic Viscosurgical Devices Market, by Distribution Channel

• 12.1. Direct Sales
• 12.2. Distributor Partners

13. Ophthalmic Viscosurgical Devices Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Ophthalmic Viscosurgical Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Ophthalmic Viscosurgical Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Alcon Inc.
• 17.2. Bausch & Lomb Incorporated
• 17.3. Canon Medical Systems Corporation
• 17.4. Carl Zeiss AG
• 17.5. ClearSight
• 17.6. Diamatrix Ltd.
• 17.7. Essilor International S.A.
• 17.8. Eyenovia, Inc.
• 17.9. F. Hoffmann-La Roche AG
• 17.10. GWS Surgicals LLP
• 17.11. Haag-Streit Group by Metall Zug
• 17.12. Halma PLC
• 17.13. HEINE Optotechnik
• 17.14. Luneau Technology Operations SAS
• 17.15. Nidek Co. Ltd.
• 17.16. Ophtec B.V.
• 17.17. Ophtechnics Unlimited
• 17.18. Paramount Surgimed Ltd.
• 17.19. Quantel Medical
• 17.20. Topcon Corporation
• 17.21. Ziemer Ophthalmic Systems AG